New Targets in Endocrine-Resistant Hormone Receptor-Positive Breast Cancer

被引：0
|
作者：
Kennedy, Laura C. [1 ]
Mayer, Ingrid A. [1 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 08期
关键词：
Endocrine resistance; hormone receptor-positive breast cancer; targeted therapy; PHASE-II TRIAL; POSTMENOPAUSAL WOMEN; AROMATASE INHIBITOR; ESTROGEN-RECEPTOR; PLUS FULVESTRANT; COMBINATION; EVEROLIMUS; SURVIVAL; THERAPY; EXEMESTANE;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Endocrine-based treatments are the backbone of initial therapy for advanced hormone receptor-positive breast cancers. Developing new therapeutic strategies to address resistance to endocrine therapy is an area of active research. In this review, we discuss targeted therapies that are currently the standard of care, as well as agents that are at present under investigation as potential treatments for advanced hormone receptor-positive breast cancer.
引用
收藏
页码：511 / 521
页数：11
相关论文
共 50 条
  • [1] Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
    Bahnassy, Shaymaa
    Thangavel, Hariprasad
    Quttina, Maram
    Khan, Ashfia Fatima
    Dhanyalayam, Dhanya
    Ritho, Joan
    Karami, Samaneh
    Ren, Jing
    Bawa-Khalfe, Tasneem
    CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)
  • [2] Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
    Shaymaa Bahnassy
    Hariprasad Thangavel
    Maram Quttina
    Ashfia Fatima Khan
    Dhanya Dhanyalayam
    Joan Ritho
    Samaneh Karami
    Jing Ren
    Tasneem Bawa-Khalfe
    Cell Communication and Signaling, 18
  • [3] Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor-Positive Breast Cancer
    Sarma, Maithreyi
    Abdou, Yara
    Dhakal, Ajay
    Gandhi, Shipra
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2020, 14
  • [4] Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer
    Nicholson, RI
    Hutcheson, IR
    Harper, ME
    Knowlden, JM
    Barrow, D
    McClelland, RA
    Jones, HE
    Wakeling, AE
    Gee, JMW
    ENDOCRINE-RELATED CANCER, 2001, 8 (03) : 175 - 182
  • [5] Sumo-modified androgen receptors support the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
    Bawa-Khalfe, Tasneem
    Bahnassy, Shaymaa
    Thangavel, Hariprasad
    Quttina, Maram
    Khan, Ashfia Fatima
    Dhanyalayam, Dhanya
    Ritho, Joan
    Karami, Samaneh
    Ren, Jing
    CANCER RESEARCH, 2021, 81 (04)
  • [6] Ethoxy mansonone G as an anticancer agent in estrogen receptor-positive and endocrine-resistant breast cancer
    Chonsut, Piriya
    Mahalapbutr, Panupong
    Pradubyat, Nalinee
    Chavasiri, Warinthorn
    Wonganan, Piyanuch
    Ketchart, Wannarasmi
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2019, 71 (12) : 1839 - 1853
  • [7] Detection of splice variants related to endocrine resistant hormone receptor-positive breast cancer
    Lee, Han-Byoel
    Kim, Min-Su
    Rhu, Jiyoung
    Park, Jung Hyun
    Kim, Kyung Eun
    Ju, Young Wook
    Lee, Eun-Shin
    Moon, Hyeong-Gon
    Noh, Dong-Young
    Kim, Sun
    Han, Wonshik
    CANCER RESEARCH, 2018, 78 (04)
  • [8] Endocrine treatment for hormone receptor-positive advanced breast cancer patients with endocrine-sensitive or endocrine-resistant disease: A systematic review and network meta-analysis
    Brandao, M.
    Maurer, C.
    Ziegelmann, P.
    Ponde, N.
    Ferreira, A. R.
    Martel, S.
    Piccart-Gebhart, M.
    Debiasi, M.
    de Azambuja, E.
    Lambertini, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [9] Epigenetic Therapy Targets Endocrine-Resistant Breast Cancer
    Genetic Engineering and Biotechnology News, 2024, 44 (04): : 34
  • [10] Mechanisms of endocrine resistance in hormone receptor-positive breast cancer
    Gao, Yuan
    Yu, Yang
    Zhang, Mingqing
    Yu, Wenjun
    Kang, Lihua
    FRONTIERS IN ONCOLOGY, 2024, 14
12345